Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab in Huntington's Disease
NCT02481674Phase 2Completed
- Sponsor
- Vaccinex, Inc.
- Start
- Jul 2015
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of pepinemab in Huntington's disease (HD), sponsored by Vaccinex, Inc.. Started Jul 2015; status: completed.
02
Drugs
pepinemab
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02481674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481674.